BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

319 related articles for article (PubMed ID: 36569863)

  • 1. The immunological role of mesenchymal stromal cells in patients with myelodysplastic syndrome.
    Zheng L; Zhang L; Guo Y; Xu X; Liu Z; Yan Z; Fu R
    Front Immunol; 2022; 13():1078421. PubMed ID: 36569863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesenchymal stromal cells from myelodysplastic and acute myeloid leukemia patients display in vitro reduced proliferative potential and similar capacity to support leukemia cell survival.
    Corradi G; Baldazzi C; Očadlíková D; Marconi G; Parisi S; Testoni N; Finelli C; Cavo M; Curti A; Ciciarello M
    Stem Cell Res Ther; 2018 Oct; 9(1):271. PubMed ID: 30359303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesenchymal stromal cells shape the MDS microenvironment by inducing suppressive monocytes that dampen NK cell function.
    Sarhan D; Wang J; Sunil Arvindam U; Hallstrom C; Verneris MR; Grzywacz B; Warlick E; Blazar BR; Miller JS
    JCI Insight; 2020 Mar; 5(5):. PubMed ID: 32045384
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
    Pleyer L; Valent P; Greil R
    Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bone marrow niche in the myelodysplastic syndromes.
    Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
    Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Cytogenetic characteristics of hematopoietic and stromal progenitor cells in myelodysplastic syndrome].
    Pimenova MA; Parovichnikova EN; Kokhno AV; Domracheva EV; Manakova TE; Mal'tseva IuS; Konnova ML; Shishigina LA; Savchenko VG
    Ter Arkh; 2013; 85(7):34-42. PubMed ID: 24137945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
    Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
    Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes.
    Mattiucci D; Maurizi G; Leoni P; Poloni A
    Cell Transplant; 2018 May; 27(5):754-764. PubMed ID: 29682980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Common and different alterations of bone marrow mesenchymal stromal cells in myelodysplastic syndrome and multiple myeloma.
    Choi H; Kim Y; Kang D; Kwon A; Kim J; Min Kim J; Park SS; Kim YJ; Min CK; Kim M
    Cell Prolif; 2020 May; 53(5):e12819. PubMed ID: 32372504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aberrant DNA methylation impacts HOX genes expression in bone marrow mesenchymal stromal cells of myelodysplastic syndromes and de novo acute myeloid leukemia.
    Roux B; Picou F; Debeissat C; Koubi M; Gallay N; Hirsch P; Ravalet N; Béné MC; Maigre M; Hunault M; Mosser J; Etcheverry A; Gyan E; Delhommeau F; Domenech J; Herault O
    Cancer Gene Ther; 2022 Aug; 29(8-9):1263-1275. PubMed ID: 35194200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transforming growth factor β1-mediated functional inhibition of mesenchymal stromal cells in myelodysplastic syndromes and acute myeloid leukemia.
    Geyh S; Rodríguez-Paredes M; Jäger P; Koch A; Bormann F; Gutekunst J; Zilkens C; Germing U; Kobbe G; Lyko F; Haas R; Schroeder T
    Haematologica; 2018 Sep; 103(9):1462-1471. PubMed ID: 29773599
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro study of biological characteristics of mesenchymal stem cells in patients with low-risk myelodysplastic syndrome.
    Zhang YZ; Zhao DD; Han XP; Jin HJ; Da WM; Yu L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Aug; 16(4):813-8. PubMed ID: 18718067
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow stromal cells from MDS and AML patients show increased adipogenic potential with reduced Delta-like-1 expression.
    Weickert MT; Hecker JS; Buck MC; Schreck C; Rivière J; Schiemann M; Schallmoser K; Bassermann F; Strunk D; Oostendorp RAJ; Götze KS
    Sci Rep; 2021 Mar; 11(1):5944. PubMed ID: 33723276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of AURKA and AURKB genes in bone marrow stromal mesenchymal cells of myelodysplastic syndrome: correlation with G-banding analysis and FISH.
    Oliveira FM; Lucena-Araujo AR; Favarin Mdo C; Palma PV; Rego EM; Falcão RP; Covas DT; Fontes AM
    Exp Hematol; 2013 Feb; 41(2):198-208. PubMed ID: 23092930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
    Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
    Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone marrow macrophages are involved in the ineffective hematopoiesis of myelodysplastic syndromes.
    Xing T; Yao WL; Zhao HY; Wang J; Zhang YY; Lv M; Xu LP; Zhang XH; Huang XJ; Kong Y
    J Cell Physiol; 2024 Feb; 239(2):e31129. PubMed ID: 38192063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
    Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
    J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo AML exhibits greater microenvironment dysregulation compared to AML with myelodysplasia-related changes.
    Lopes MR; Pereira JK; de Melo Campos P; Machado-Neto JA; Traina F; Saad ST; Favaro P
    Sci Rep; 2017 Jan; 7():40707. PubMed ID: 28084439
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The different immunoregulatory functions on dendritic cells between mesenchymal stem cells derived from bone marrow of patients with low-risk or high-risk myelodysplastic syndromes.
    Wang Z; Tang X; Xu W; Cao Z; Sun L; Li W; Li Q; Zou P; Zhao Z
    PLoS One; 2013; 8(3):e57470. PubMed ID: 23469196
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impairment of PI3K/AKT and WNT/β-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes.
    Falconi G; Fabiani E; Fianchi L; Criscuolo M; Raffaelli CS; Bellesi S; Hohaus S; Voso MT; D'Alò F; Leone G
    Exp Hematol; 2016 Jan; 44(1):75-83.e1-4. PubMed ID: 26521017
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.